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Introduction: A recent genome-wide association study (GWAS) comprising a French cohort of systemic sclerosis
(SSc) reported several non-HLA single-nucleotide polymorphisms (SNPs) showing a nominal association in
the discovery phase. We aimed to identify previously overlooked susceptibility variants by using a follow-up
strategy.
Methods: Sixty-six non-HLA SNPs showing a P value <10-4 in the discovery phase of the French SSc GWAS were
analyzed in the first step of this study, performing a meta-analysis that combined data from the two published
SSc GWASs. A total of 2,921 SSc patients and 6,963 healthy controls were included in this first phase. Two SNPs,
PPARG rs310746 and CHRNA9 rs6832151, were selected for genotyping in the replication cohort (1,068 SSc
patients and 6,762 healthy controls) based on the results of the first step. Genotyping was performed by using
TaqMan SNP genotyping assays.
Results: We observed nominal associations for both PPARG rs310746 (PMH = 1.90 × 10
-6, OR, 1.28) and CHRNA9
rs6832151 (PMH = 4.30 × 10
-6, OR, 1.17) genetic variants with SSc in the first step of our study. In the replication
phase, we observed a trend of association for PPARG rs310746 (P value = 0.066; OR, 1.17). The combined overall
Mantel-Haenszel meta-analysis of all the cohorts included in the present study revealed that PPARG rs310746
remained associated with SSc with a nominal non-genome-wide significant P value (PMH = 5.00 × 10
-7; OR, 1.25).
No evidence of association was observed for CHRNA9 rs6832151 either in the replication phase or in the overall
pooled analysis.
Conclusion: Our results suggest a role of PPARG gene in the development of SSc.* Correspondence: martin@ipb.csic.es
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Systemic sclerosis (SSc) is a complex autoimmune disease
with heterogeneous clinical manifestations characterized
by extensive fibrosis in the skin and multiple internal
organs, vascular damage, and immune imbalance with
autoantibody production [1]. SSc patients are commonly
classified in two major subtypes: limited cutaneous SSc
(lcSSc) and diffuse cutaneous SSc (dcSSc), the latter with
more progressive fibrosis of the skin, lungs, and other
internal organs and, ultimately, with worse prognosis [2].
The etiology of this disorder is still unclear. However,
epidemiologic and genetic studies clearly reflect the
existence of a complex genetic component together with
the influence of environmental factors [1]. During recent
years, great advances have been made in our knowledge
of the genetic basis of SSc [3,4], in part, thanks to
the two independent genome-wide associations studies
(GWASs) conducted in Caucasian populations that have
been recently published [5,6], and several consequent
follow-up studies [7-10].
However, despite these advances, the number of cur-
rently known loci explaining the genetic component of
SSc is limited. To date, 13 loci have been identified as
genetic risk factors for SSc at the genome-wide signifi-
cance level. In other autoimmune diseases with multifac-
torial inheritance, such as Crohn disease, ulcerative colitis,
or systemic lupus erythematosus, individual GWAS scans
and follow-up meta-analyses have identified more than 71,
47, and 35 susceptibility loci, respectively [11-13]. There-
fore, it is expected that additional risk factors for SSc
remain to be discovered, and further meta-analyses and
large replication studies are needed to identify part of the
missing heritability of this disease.
Follow-up studies focused on the so-called grey zone of
the GWASs, where SNPs with tier 2 associations (P values
between 5 × 10-8 and 5 × 10-3) are located, constitute one
of the most useful GWAS data-mining methods, because
possible real association signals could be masked in that
area because of a lack of statistical power. On this basis,
we aimed to perform a follow-up study of the SNPs
located in the grey zone of the GWAS by Allanore et al.
[6], taking advantage of our GWAS data sets. We
hypothesize that using a larger cohort would increase the
statistical power and might lead to the identification of
new suitable SSc genetic risk factors.
Methods
Study design
In the first step of this study, we focused on the 90
GWAS-genotyped SNPs that reached a P value < 10-4 in
the discovery phase of the GWAS carried out by Allanore
et al. [6]. Then, we analyzed the SNPs overlapping with
those included in Radstake et al. [5]. After excluding
those SNPs located within MHC genes or in previouslyassociated loci, data for 66 SNPs were selected. A meta-
analysis including these 66 SNPs was performed on the
combined data set from the two SSc GWASs, sho-
wing only two SNPs (rs310746 PPARG and rs6832151
CHRNA9 genetic variants) with a P value < 10-5 (see later).
These two genetic variants were genotyped in indepen-
dent replication cohorts. Finally, we performed a meta-
analysis for these two selected SNPs combining genotype
data from both first and replication steps.
Study population
The first step of the study comprised a total of 2,921 SSc
patients and 6,963 healthy controls of Caucasian ancestry
from two previously published GWASs (European, USA,
and French) [5,6]. The replication cohort was composed
of 1,068 SSc patients and 1,490 healthy controls from two
case–control sets of European ancestry (Italy and United
Kingdom). We also included 5,272 extra English controls
from The Wellcome Trust Case Control Consortium for
the replication step comprising a total of 6,762 controls
for this stage.
All SSc patients fulfilled the classification criteria by
LeRoy et al. [2]. Approval from the local ethical com-
mittees (Comité de Bioética del Consejo Superior de
Investigaciones Científicas, U.O. Comitato di Etica e
Sperimentazione Farmaci Fondazione IRCCS Ca’ Granda,
Ospedale Maggiore Policlinico di Milano, Comitato Etico
Azienda Ospedaliera Universitaria Integrata di Verona,
The Ethics Committee of the Spedali Civili, Brescia, Royal
Free Hospital and Medical School Research Ethics Com-
mittee, Manchester University Research Ethics Commit-
tee, Local Research Ethics Committee at Glasgow Royal
Infirmary, Newcastle University Ethics Committee, Ethical
Committee of the University Erlangen-Nuremberg, Local
Ethics Committee of the Radboud University Nijmegen
Medical Centre, Medical Ethics Review Committee of
the VU University, Medische Ethische Commissie Leids
Universitair Medisch Centrum, Ethics Review Board of
the Ruhr University Bochum, Ethics Committee of the
University of Cologne, Ethical Committee from the
Charité University Hospital, Ethik-Kommission der MHH,
Internal Review Board of Texas University), and written
informed consents from all participants were obtained in
accordance with the tenets of the Declaration of Helsinki.
Genotyping
In the first stage, genotype data for the 66 selected SNPs
were obtained from both published SSc GWASs [5,6].
QC filters and principal component analysis were ap-
plied to the GWASs data, as described in Radstake et al.
[5] and Allanore et al. [6].
In the replication phase, DNA from patients and con-
trols was obtained by using standard methods. Genotyping
was performed by using TaqMan 5′ allele discrimination
Table 1 Meta-analysis of 66 GWAS-genotyped SNPs in scleroderma (SSc) patients and healthy controls of
Caucasian origin
Chr Locus SNP Minor/major MAF cases MAF controls PMH OR (CI 95%)
a PBD
3 PPARG rs310746 C/T 0.108 0.086 1.90E-06 1.28 [1.12-1.47] 0.33
4 CHRNA9 | RHOH rs6832151 G/T 0.315 0.281 4.30E-06 1.17 [1.075-1.27] 0.05
2 DYSF rs11692280 A/G 0.195 0.220 2.31E-04 0.86 [0.80-0.93] 0.04
4 PGDS rs17021463 T/G 0.393 0.421 2.45E-04 0.89 [0.83-0.94] 0.13
22 DGCR6 rs2543958 G/T 0.127 0.109 4.98E-04 1.18 [1.09-1.28] 0.09
17 ORMDL3/GSDML rs8079416 C/T 0.435 0.461 1.13E-03 0.90 [0.85-0.94] 0.01
1 - rs6679637 A/G 0.100 0.116 2.35E-03 0.85 [0.77-0.94] 0.03
1 CSFR3 rs4653210 G/T 0.111 0.122 3.71E-03 0.86 [0.78-0.95] 0.02
3 PPARG/ TSEN2 rs9855622 T/C 0.124 0.110 4.75E-03 1.14 [1.01-1.30] 2.94E-03
7 CACNA2D1 rs1544461 A/G 0.429 0.409 5.14E-03 1.09 [1.02-1.16] 7.81E-04
18 CNDP2 rs2241508 G/A 0.421 0.401 5.26E-03 1.09 [1.03-1.15] 2.94E-04
11 PHF21A/CREB3L1 rs7128538 A/G 0.491 0.470 5.51E-03 1.09 [1.02-1.16] 4.62E-03
14 NPAS3 rs1299512 G/A 0.228 0.211 7.76E-03 1.10 [1.00-1.21] 0.05
13 RFC3 rs7335534 G/A 0.398 0.415 8.61E-03 0.91 [0.84-0.99] 7.34E-04
8 DDEF1 rs7817803 A/C 0.437 0.421 0.012 1.08 [1.01-1.15] 2.01E-03
8 DDE/ rs3057 C/T 0.439 0.423 0.012 1.08 [1.01-1.15] 1.13E-03
17 TMEM132E/CCDC16 rs887081 T/G 0.115 0.129 0.013 0.88 [0.810.95] 5.33E-03
5 CDH18 rs1911856 T/C 0.059 0.048 0.013 1.18 [1.03-1.35] 3.24E-03
7 CAV1 rs2402091 A/G 0.110 0.122 0.014 0.88 [0.80-0.97] 0.02
7 - rs1228966 A/G 0.222 0.208 0.015 1.09 [1.01-1.18] 2.29E-03
7 SEMA3A rs1228870 T/G 0.222 0.208 0.017 1.09 [1.01-1.18] 3.15E-03
5 LOC389293 rs7708428 G/A 0.401 0.418 0.019 0.92 [0.87-0.98] 0.01
9 XPA rs2808699 A/C 0.403 0.423 0.021 0.92 [0.87-0.98] 2.38E-04
8 DDEF1 rs7839523 G/T 0.440 0.425 0.021 1.07 [1.011-1.14] 1.10E-03
9 XPA rs2805790 A/G 0.403 0.422 0.022 0.92 [0.87-0.98] 3.37E-04
3 IRAK2 rs11706450 T/C 0.465 0.482 0.024 0.93 [0.86-1.01] 9.00E-03
9 XPA rs2805815 A/G 0.403 0.422 0.024 0.93 [0.87-0.99] 3.02E-04
2 NOL10 rs4668690 A/G 0.067 0.059 0.026 1.15 [1.01-1.30 3.10E-03
7 - rs1029541 T/C 0.230 0.219 0.028 1.08 [1.01-1.17] 8.07E-04
9 XPA rs2668797 A/G 0.071 0.112 0.029 0.933 [0.87-0.99] 2.48E-04
14 - rs1036570 A/G 0.322 0.335 0.032 0.92 [0.85-1.014] 2.13E-03
3 - rs4128236 T/C 0.322 0.306 0.034 1.07 [0.98-1.17] 3.87E-04
1 - rs10925871 A/G 0.193 0.181 0.038 1.08 [1.00-1.17] 6.22E-03
7 CADPS2 rs2501439 G/A 0.418 0.432 0.042 0.93 [0.87-0.99] 7.49E-03
7 - rs757747 T/C 0.229 0.218 0.047 1.07 [1.00-1.16] 1.29E-03
7 WBSCR17 rs4585627 T/C 0.323 0.308 0.051 1.07 [1.00-1.14] 4.70E-03
10 - rs1254860 C/T 0.110 0.100 0.064 1.09 [0.99-1.21] 0.03
8 DDEF1 rs6470805 G/A 0.333 0.344 0.069 0.94 [0.88-1.00] 4.88E-03
9 LCN9 rs541131 G/A 0.400 0.385 0.071 1.06 [0.99-1.12] 1.78E-03
5 CDH18 rs2202798 T/C 0.080 0.069 0.078 1.11 [0.98-1.24] 9.17E-04
3 TDGF1 rs6799581 G/T 0.260 0.268 0.080 0.94 [0.86-1.03] 6.85E-04
5 CDH18 rs12655266 A/G 0.074 0.065 0.111 1.10 [0.98-1.24] 1.09E-03
4 NPY2R rs2880417 G/A 0.292 0.281 0.117 1.05 [0.99-1.13] 2.07E-05
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Table 1 Meta-analysis of 66 GWAS-genotyped SNPs in scleroderma (SSc) patients and healthy controls of
Caucasian origin (Continued)
7 - rs10272701 T/C 0.192 0.183 0.130 1.06 [0.98-1.15] 7.73E-03
8 FBX032 rs3739284 C/T 0.219 0.224 0.148 0.94 [0.87-1.01] 3.71E-03
6 ASCC3 rs7771570 C/T 0.492 0.482 0.153 1.04 [0.98-1.11] 2.97E-04
18 PHLPP rs2877745 T/C 0.091 0.084 0.158 1.08 [0.98-1.18] 3.49E-03
21 - rs2831511 T/C 0.393 0.403 0.175 0.95 [0.90-1.01] 1.54E-04
11 OPCML rs10894623 T/G 0.291 0.281 0.175 1.04 [0.95-1.14] 8.98E-04
6 ASCC3 rs6919745 T/C 0.476 0.467 0.190 1.042 [0.98-1.11] 1.88E-04
4 NPY2R rs13138293 G/T 0.308 0.299 0.195 1.05 [0.97-1.11] 8.20E-05
15 SMAD3 rs4147358 A/C 0.237 0.243 0.203 0.95 [0.86-1.04] 4.76E-04
17 TMEM132E rs4795032 T/C 0.351 0.341 0.232 1.04 [0.95-1.13] 6.65E-04
9 - rs10756265 A/G 0.342 0.352 0.251 0.96 [0.90-1.02] 2.18E-04
9 - rs443042 G/A 0.366 0.376 0.261 0.96 [0.90-1.02] 2.01E-04
9 SUSD3 rs9696357 T/C 0.154 0.160 0.268 0.95 [0.87-1.03] 2.11E-03
12 SFRS8 rs10794423 C/T 0.439 0.442 0.282 0.96 [0.89-1.04] 1.22E-03
2 ATP6V1C2 rs7422405 A/G 0.428 0.433 0.385 0.97 [0.91-1.03] 1.93E-04
3 RBMS3 rs35883 A/G 0.457 0.4564 0.556 1.019 [0.94-1.10] 1.04E-04
21 CHODL/ PRSS7 rs2248200 C/T 0.484 0.4815 0.598 1.01 [0.96-1.07] 1.35E-03
21 CHODL/PRSS7 rs1688165 A/G 0.485 0.4820 0.628 1.01 [0.96-1.07] 8.62E-04
16 ZNF423 rs1477020 T/C 0.121 0.1235 0.649 0.97 [0.86-1.10] 8.30E-06
1 C1QB rs631090 C/T 0.073 0.0702 0.729 1.02 [0.90-1.15] 3.73E-04
16 ZNF423 rs1990629 G/A 0.128 0.1308 0.736 0.98 [0.87-1.10] 2.13E-05
11 OPCML rs11223273 T/C 0.275 0.2721 0.759 1.01 [0.92-1.10] 1.40E-04
19 TSPAN16 rs322151 T/C 0.252 0.2527 0.990 0.99 [0.94-1.06] 3.37E-04
N, 2,921 SSc/6,963 controls. aOdds ratio for the minor allele. Chr, chromosome; CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; PBD, Breslow–Day test
P value; PMH, allelic Mantel-Haenszel fixed effects model P value; SNP, single nucleotide polymorphism.
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ID: C___8756618_10; rs6832151 ID: C__29224385_10,
Foster City, CA, USA) in both 7900HT Fast Real-Time
PCR System (Applied Biosystems, Foster City, CA, USA),
and LightCycler 480 Real-Time PCR System (Roche Ap-
plied Science, Mannheim, Germany). Genotyping call rate
was > 98% for both genotyped SNPs.
Statistical analysis
Association analyses of the genotype data was carried out
with StatsDirect V.2.6.6 (StatsDirect, Altrincham, UK) and
PLINK V.1.07 [14] software. Statistical significance was
calculated by 2 × 2 contingency tables and χ2 or Fisher
Exact test, when necessary, to obtain P values, odds
ratios (ORs), and 95% confidence intervals (CIs) in the
population-specific analyses. Mantel-Haenszel tests under
fixed effects or random effects, when appropriate, were
performed to meta-analyze the combined data. Breslow–
Day method (BD) was used to assess the homogeneity
of the associations among the different populations
(Breslow–Day P values <0.05 were considered statistically
significant). Hardy-Weinberg equilibrium (HWE) wastested for all cohorts (HWE P values lower than 0.01 were
considered to show significant deviation from the equili-
brium). None of the included cohorts showed significant
deviation from HWE for the two genotyped SNPs. Since
the analyses were performed by using GWAS data, the
statistical threshold for considering a P value as a signifi-
cant P value in the allelic association analyses was set at
5 × 10-8.
The statistical power of the combined analysis was
70% for the PPARG rs310746 and 100% for the CHRNA9
rs6832151 to detect associations with OR = 1.3 and a
statistical significance of 5 × 10-8, according to Power
Calculator for Genetic Studies 2006 software [15].
Results
Table 1 shows the results of the 66 GWAS-genotyped
SNPs selected for the combined meta-analysis of the two
GWAS data sets performed in the first step of this study
(see Additional file 1: Table S1 provides the results from
both GWASs and the combined meta-analysis for the 66
selected SNPs). Two SNPs showed a P value lower than
10-5 (PPARG rs310746: PMH = 1.90 × 10
-6; OR, 1.28; CI,
Table 2 Analysis of rs310746 and rs6832151 minor allele frequencies in the GWASs, replication, and combined cohorts
Cohort, N (cases/controls) Chr Locus SNP Minor/major MAF cases MAF controls PMH OR (CI 95%)
a PBD
GWASs 3 SYN2|PPARG rs310746 C/T 0.108 0.087 1.90E-06 1.28 [1.12-1.47] 0.334
2921/6963 4 CHRNA9|RHOH rs6832151 G/T 0.315 0.282 4.30E-06 1.17 [1.075-1.27] 0.054
Replication 3 SYN2|PPARG rs310746 C/T 0.099 0.103 0.066 1.17 [0.99-1.38] 0.231
1068/6762 4 CHRNA9|RHOH rs6832151 G/T 0.296 0.280 0.962 0.99 [0.89-1.11] 0.934
Combined 3 SYN2|PPARG rs310746 C/T 0.106 0.094 5.00E-07 1.25 [1.15-1.37] 0.324
3989/13725 4 CHRNA9|RHOH rs6832151 G/T 0.310 0.281 1.07E-04b 1.12 [1.06-1.19] 0.017
aOdds ratio for the minor allele. bP value from meta-analysis under random effects = 0.051; OR = 1.10 (0.99-1.22).
Chr, chromosome; CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; PBD, Breslow–Day test P value; PMH, allelic Mantel-Haenszel fixed-effects
model P value; SNP, single-nucleotide polymorphism.
López-Isac et al. Arthritis Research & Therapy 2014, 16:R6 Page 5 of 8
http://arthritis-research.com/content/16/1/R695%, 1.12 to 1.47; and CHRNA9 rs6832151: PMH = 4.30 ×
10-6, OR, 1.17; CI 95%, 1.08 to 1.27), and presented no sig-
nificant Breslow-Day P values (PBD) showing homogeneity
in the ORs among populations. Therefore, these two
SNPs were selected to genotype in independent co-
horts. Patients and healthy controls were found to be
in HWE at 1% significance level for both selected
SNPs.
In the replication phase, we observed a trend of asso-
ciation for the PPARG rs310746 genetic variant (P value =
0.066; OR = 1.17; CI 95%, 0.99 to 1.38) in the combined
analysis of the two replication cohorts (Table 2, upper
rows). However, no evidence of association was observed
for CHRNA9 rs6832151 either in the pooled analysis
(Table 2, upper rows) or in the analysis of each individual
population (see Additional file 2: Table S2).
Finally, we combined the results from both steps of the
study and performed a Mantel-Haenszel meta-analysis ob-
serving that the PPARG genetic variant showed suggestiveFigure 1 Forest plots of PPARG rs310746 and CHRNA9 rs6832151. For
PPARG rs310746 (under a fixed-effects model) and CHRNA9 rs6832151 (unde
combined analysis.evidence of association with SSc (PMH = 5.00 × 10
-7; OR =
1.25; CI, 95%, 1.15 to 1.37) (Table 2, lower rows; Figure 1).
However, CHRNA9 rs6832151 showed no evidence of
association with the disease when the meta-analysis
was performed either under a random-effects model
(heterogeneity of the ORs was observed for this SNP;
P value = 5.10 × 10-2, OR = 1.10; CI 95%, 0.99 to 1.22), or
a fixed-effects model (P value = 1.07 × 10-4; OR = 1.12;
CI 95%, 1.06 to 1.19) (Table 2, lower rows; Figure 1).
Discussion
In this study we conducted a meta-analysis combining
previously published SSc GWASs data for 66 SNPs and
analyzed the possible role of two selected SNPs, PPARG
rs310746 and CHRNA9 rs6832151, in SSc risk by using
independent replication cohorts.
Meta-analyses are a useful tool to increase the statis-
tical power of genetic studies, thus improving the ac-
curacy of the estimations of statistical significance. Ofest plots showing the odds ratios and confidence intervals of both
r a random-effects model) in all the populations included in the
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tend to have inflated effect sizes [16]. On this basis, our
data suggest that most signals from the grey zone observed
in the discovery phase of the GWAS by Allanore et al. [6]
presented inflated effect sizes, also called the winner’s
curse. In fact, this effect was already observed in the repli-
cation study conducted by our group for the novel SSc
genetic risk factors identified by Allanore et al. [6], in
which we could not replicate the association described for
RHOB [17].
Our overall combined meta-analysis showed that the as-
sociation of the PPARG rs310746 genetic variant with SSc
remained with a nominal but non-genome-wide signifi-
cant P value. This SNP is located upstream of PPARG,
which encodes the peroxisome proliferator-activated re-
ceptor gamma (PPARG). PPARG was initially identified in
adipose tissue, where this nuclear receptor plays impor-
tant roles in adipogenesis, insulin sensitivity, and ho-
meostasis [18]. Interestingly, during recent years, several
studies have identified a novel role of PPARG as an antifi-
brotic effector. Thus, it has been reported that fibroblasts
exposure to pharmacologic PPARG ligands give rise to
suppression of collagen synthesis, myofibroblast diffe-
rentiation, and other TGF-β-induced fibrotic responses
in vitro [19-21]. Moreover, functional studies showed that
PPARG agonist attenuated dermal fibrosis in mice with
bleomycin-induced scleroderma [22,23].
These findings are remarkable in SSc, in which fibrosis
is one of the main hallmarks of the disease. In this regard,
Wei et al. [24] demonstrated that PPARG expression and
function are impaired in SSc patients. Therefore, defects
in PPARG expression may influence the uncontrolled pro-
gression of fibrosis in SSc. In addition, PPARG has been
associated with other autoimmune diseases, such as in-
flammatory bowel disease [25,26] and psoriatic arthritis
[27], and it is also a confirmed susceptibility locus in type
2 diabetes mellitus [28].
Although PPARG was the most likely biologic candi-
date gene for the reported suggestive association signal,
we could not rule out TIMP4 as another possible gene
for this signal. Further analyses are required to elucidate
the functional implication of the reported signal.
Regarding the CHRNA9 genetic variant, despite the sug-
gestive association found in the first step of the present
study, the overall combined meta-analysis did not show
evidence of association with SSc. Moreover, the effect
size of the analyzed genetic variant was heterogeneous
between the different populations. Although our data
showed heterogeneity and lack of association in this locus,
a slight or modest effect of CHRNA9 cannot be ruled out,
and further studies will be required to determine whether
this region is associated with SSc.
It is worth mentioning that the analyzed CHRNA9
SNP has been previously associated with Graves disease(first, through a GWAS performed in the Chinese Han
population [29], and subsequently, in a replication study
performed in a Polish Caucasian population [30]), but
this is the only reported association between this gene
and an autoimmune disease.
Conclusion
In conclusion, we report a suggestive association between
PPARG rs310746 and SSc. However, further studies are
needed to establish this locus firmly as a new susceptibility
SSc genetic risk factor.
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